Wu W - Search Results

1

Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians.

Zhou H, Luo Q, Wu W, Li N, Yang C, Zou L. Zhou H, et al. Among authors: wu w. Front Immunol. 2023 Mar 1;14:1088874. doi: 10.3389/fimmu.2023.1088874. eCollection 2023. Front Immunol. 2023. PMID: 36936913 Free PMC article. Review.

2

Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy.

Luo Q, Yang C, Fu C, Wu W, Wei Y, Zou L. Luo Q, et al. Among authors: wu w. Front Oncol. 2021 Apr 29;11:639644. doi: 10.3389/fonc.2021.639644. eCollection 2021. Front Oncol. 2021. PMID: 33996552 Free PMC article.

3

How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome.

Li N, Jiang M, Wu WC, Wei WW, Zou LQ. Li N, et al. Front Oncol. 2021 Aug 18;11:704962. doi: 10.3389/fonc.2021.704962. eCollection 2021. Front Oncol. 2021. PMID: 34490105 Free PMC article.

4

Evaluation of different staging systems and prognostic analysis of nasal-type extranodal NK/T-cell lymphoma based on consistent LVDP chemotherapy regimen.

Wu W, Ren K, Li N, Luo Q, Xu C, Zou L. Wu W, et al. Transl Oncol. 2022 Jul;21:101437. doi: 10.1016/j.tranon.2022.101437. Epub 2022 Apr 27. Transl Oncol. 2022. PMID: 35489119 Free PMC article.

5

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.

Chen X, Wu W, Wei W, Zou L. Chen X, et al. Among authors: wu w. Front Pharmacol. 2022 Apr 26;13:869488. doi: 10.3389/fphar.2022.869488. eCollection 2022. Front Pharmacol. 2022. PMID: 35559250 Free PMC article. Review.

6

First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.

Wu W, Chen X, Li N, Luo Q, Zou L. Wu W, et al. Ann Hematol. 2022 Jul;101(7):1557-1565. doi: 10.1007/s00277-022-04828-5. Epub 2022 May 18. Ann Hematol. 2022. PMID: 35585247

7

The value of prognostic nutritional index in nasal-type, extranodal natural killer/T-cell lymphoma.

Li N, Jiang M, Wu WC, Zou LQ. Li N, et al. Ann Hematol. 2022 Jul;101(7):1545-1556. doi: 10.1007/s00277-022-04849-0. Epub 2022 May 30. Ann Hematol. 2022. PMID: 35635579

8

¹⁸F-FDG PET/CT Plays a Limited Role in Replacing Bone Marrow Biopsy for Newly Diagnosed Advanced-Stage Patients With Extranodal Natural Killer/T-Cell Lymphoma.

Yang C, Wu W, Zhou H, Zhao S, Tian R, Xiang M, Zou L. Yang C, et al. Among authors: wu w. Front Oncol. 2022 Jul 26;12:894804. doi: 10.3389/fonc.2022.894804. eCollection 2022. Front Oncol. 2022. PMID: 35965550 Free PMC article.

9

Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center.

Li N, Jiang M, Wu WC, Zhou HJ, Zou LQ. Li N, et al. Hematology. 2022 Dec;27(1):909-916. doi: 10.1080/16078454.2022.2113600. Hematology. 2022. PMID: 35993333 Free article.

10

Nomograms to predict progression of disease within 24 months in patients with localized natural killer/T-cell lymphoma.

Li N, Jiang M, Wu WC, Zou LQ. Li N, et al. Future Oncol. 2022 Oct;18(32):3573-3583. doi: 10.2217/fon-2022-0307. Epub 2022 Dec 12. Future Oncol. 2022. PMID: 36507722

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30,773 results

Search Page

Filters